Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis
Complement-mediated damage to the neuromuscular junction (NMJ) is a key mechanism of pathology in myasthenia gravis (MG), and therapeutics inhibiting complement have shown evidence of efficacy in the treatment of MG. In this study, we describe the development of a subcutaneously administered N-acety...
Main Authors: | Linda L. Kusner, Kristina Yucius, Manjistha Sengupta, Andrew G. Sprague, Dhruv Desai, Tuyen Nguyen, Klaus Charisse, Satya Kuchimanchi, Rajeev Kallanthottathil, Kevin Fitzgerald, Henry J. Kaminski, Anna Borodovsky |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-06-01
|
Series: | Molecular Therapy: Methods & Clinical Development |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2329050119300452 |
Similar Items
-
Serum metabolomic response of myasthenia gravis patients to chronic prednisone treatment.
by: Manjistha Sengupta, et al.
Published: (2014-01-01) -
MicroRNA and mRNA expression associated with ectopic germinal centers in thymus of myasthenia gravis.
by: Manjistha Sengupta, et al.
Published: (2018-01-01) -
The Role of Osteopontin and Its Gene on Glucocorticoid Response in Myasthenia Gravis
by: Yanchen Xie, et al.
Published: (2017-05-01) -
Editorial: Advances in Autoimmune Myasthenia Gravis
by: Anna Rostedt Punga, et al.
Published: (2020-08-01) -
Complement Inhibitor Therapy for Myasthenia Gravis
by: Khaled Albazli, et al.
Published: (2020-06-01)